Core Viewpoint - The company has completed clinical trials for its product "Recombinant Type III Humanized Collagen Freeze-Dried Fiber" and is now ready to submit registration application materials [1] Group 1 - The clinical trial summary report has been obtained, indicating successful completion of the trials [1] - The clinical application of the product focuses on improving skin condition through moisturizing and hydrating effects of the recombinant type III humanized collagen [1]

Group 1 - The core viewpoint of the news is that Guoen Technology, a Chinese chemical materials supplier, has successfully completed its IPO subscription, raising significant interest from investors with an oversubscription rate of 878 times [1] - Guoen Technology plans to issue 30 million H-shares, with 10% allocated for Hong Kong and 90% for international offerings, and has a total fundraising target of up to 1.26 billion HKD [1] - The company has attracted eight cornerstone investors, raising a total of approximately 320 million HKD [1] Group 2 - Guoen Technology, founded in 2000, specializes in chemical new materials and gelatin, serving both the chemical and health industries [2] - The company is the second-largest producer of bone gelatin in China and the largest domestic brand, as well as the second-largest domestic brand in the hollow capsule industry, according to Frost & Sullivan [2] - Financially, the company reported revenues of approximately 13.406 billion RMB, 17.439 billion RMB, 19.188 billion RMB, and 17.444 billion RMB for the fiscal years 2022, 2023, 2024, and the first ten months of 2025, respectively [2] Group 3 - The net proceeds from the IPO are expected to be approximately 1.058 billion HKD, with 50% allocated to expanding production capacity in Thailand, 35% for new production capacity in China, 10% for investments in Hong Kong, and 5% for operational funds [3]

Core Viewpoint - The company, Guo'en Technology, is set to launch an IPO from January 27 to January 30, 2026, offering 30 million shares globally, with a price range of HKD 34.00 to HKD 42.00 per share, and aims to raise approximately HKD 1.058 billion for expansion and operational purposes [1][5]. Group 1: Company Overview - Guo'en Technology specializes in chemical new materials and gelatin, collagen, and related products, serving both the chemical and health industries [1]. - The company focuses on R&D, production, and sales of industrial and commercial products, catering to manufacturers in downstream sectors such as automotive, new energy, and home appliances [1]. Group 2: Chemical Industry Segment - In the chemical industry, the company has a comprehensive product range that includes upstream green petrochemical materials and midstream organic polymer modified materials [2]. - The company is the second-largest player in China's organic polymer modified materials and organic polymer composite materials market, with a market share of 2.5% as of 2024 [2]. - It is also the largest producer of polystyrene in China by production capacity as of 2024 [2]. Group 3: Health Industry Segment - In the health sector, the company focuses on the natural collagen industry, with a vertical integration strategy that spans from collagen to end products [3]. - The company is the second-largest producer of bone gelatin in China by output and the largest domestic brand in this category as of 2024 [3]. - It ranks as the second-largest domestic brand in the hollow capsule production sector in China by output as of 2024 [3]. Group 4: Investment and Fund Allocation - The company has secured cornerstone investment agreements totaling approximately HKD 320 million, with investors including several financial institutions [4]. - The net proceeds from the IPO are expected to be around HKD 1.058 billion, with allocations planned for expanding production capacity in Thailand (50%), China (35%), and investments in Hong Kong (10%) [5].

Core Insights - The strategic partnership between Yuansong Group and Chongshan Biotechnology has led to the launch of the world's first collagen product derived from bovine tendons, named "Jiaoyuan Angel," which received regulatory approval on December 10 [1][3] - The collagen market has reached a scale of 200 billion and is projected to grow to 500 billion by 2030, indicating significant growth potential in the industry [3] Product Advantages - "Jiaoyuan Angel" features a high medical collagen concentration of 45 mg/ml, ensuring strong support [5] - The product uses collagen extracted from bovine tendons, ensuring high purity and structural integrity [5] - Advanced application technology allows for precise subcutaneous implantation, providing deeper network support for the skin [5] - The company has addressed industry challenges, establishing 45 mg/ml as the optimal concentration to balance efficacy and safety [5] Market Positioning - The collaboration signifies an upgrade in the synergy between clinical institutions and research enterprises, aiming to redefine the application of collagen in the market [6] - The focus is shifting from "volume enhancement" to "nutritional tightening," which is expected to become the mainstream trend in the collagen market [8] - Yuansong Group has previously launched several successful products in the medical beauty sector, positioning itself as a market leader [8] - "Jiaoyuan Angel" is anticipated to capture significant market share and potentially become a dark horse in the medical beauty market by 2026 due to its technological advantages and promotional capabilities [8]

Core Insights - The world's first collagen product derived from beef tendon will be launched by Yuansong on January 2, marking a significant development in the collagen market [1] - Yuansong Group has formed a strategic partnership with Chongshan Biotechnology to combine their technological advantages, aiming to shift the collagen field from "volume enhancement" to "nutritional tightening" [1] - The collagen market, currently valued at 200 billion, is projected to reach 500 billion by 2030, driven by applications in medical, beauty, and health sectors [1] Company Developments - Chongshan Biotechnology's "Jiaoyuan Angel," the first beef tendon collagen implant, received approval from the National Medical Products Administration on December 10 [1] - With the approval of Jiaoyuan Angel, the number of collagen products with Class III medical device certification in China has increased to 15, although only one-third of these products have become mainstream [1] - Chongshan's chairman highlighted that Jiaoyuan Angel stands out due to its redefined core dimensions in ingredient concentration, material source, and application technology [1] Industry Trends - The collaboration between Yuansong Group and Chongshan Biotechnology signifies an upgrade in the collaborative model between clinical institutions and research enterprises [1] - The new product is not just an addition but is intended to create a comprehensive treatment plan that integrates anti-aging medicine, natural aesthetics, and material science [1]

Investment Rating - The report maintains a "Buy" rating for the company [2][16]. Core Insights - The approval of the first recombinant type I natural sequence collagen facial injection product in China marks a significant milestone for the company, enhancing its competitive position in the medical aesthetics market [7]. - The new product is expected to drive revenue growth and reshape the competitive landscape in the collagen product category, showcasing the company's technological and industrial capabilities [7]. - The company has demonstrated strong revenue growth across its product lines, with notable performance from its flagship products and new launches [7]. Financial Data and Profit Forecast - Projected revenue growth from 2023 to 2027 shows a significant increase, with revenues expected to rise from 3,524 million RMB in 2023 to 10,691 million RMB in 2027, reflecting a compound annual growth rate (CAGR) of approximately 49% [6][8]. - The net profit attributable to the parent company is forecasted to grow from 1,452 million RMB in 2023 to 3,726 million RMB in 2027, with a CAGR of around 23% [6][8]. - The company's gross margin is expected to remain stable, averaging around 82% over the forecast period [6]. Product Performance and Market Position - The flagship product, "可复美," generated revenue of 25.4 billion RMB in the first half of 2025, representing a year-on-year growth of 22.7% [7]. - The company has successfully launched new products that have gained market recognition, contributing to overall revenue growth [7]. - Direct sales channels have shown strong growth, with direct sales revenue reaching 23.3 billion RMB in the first half of 2025, up 26.5% year-on-year [7].

Core Viewpoint - Huaxi Biological is accelerating its transformation by shutting down the Runxiquan brand, which has not significantly contributed to its revenue and profit, as part of a strategy to focus on its main business and key brands [2][5][6]. Brand Adjustment - The closure of the Runxiquan brand has been confirmed, with its official stores on platforms like Taobao no longer searchable and its products cleared from its Douyin flagship store [4][6]. - Huaxi Biological emphasized that Runxiquan was never a major brand for the company and its existence did not meaningfully impact revenue or profit [4][7]. Financial Performance - In 2024, Huaxi Biological's functional skincare business generated revenue of 2.569 billion yuan, a year-on-year decline of 31.62% [8]. - The revenue contributions from the four main brands—Runbaiyan (922 million yuan), Kuaidi (649 million yuan), Mibeier (290 million yuan), and BM Jihuo (279 million yuan)—showed significant declines, with year-on-year drops of 22.63%, 41.69%, 31.76%, and 52.06% respectively [8][9]. - Overall, Huaxi Biological's revenue and net profit decreased by 19.57% and 35.38% respectively in the first half of 2025, following an 11.61% and 70.59% decline in 2024 [8][9]. Market Challenges - The functional skincare sector is facing a development bottleneck, with increasing competition and a saturated market limiting growth opportunities for brands like Runxiquan [7][12]. - Huaxi Biological's past success was heavily reliant on "traffic operation," and rising traffic costs have led to a stagnation in performance growth [9][12]. Strategic Transformation - The company is undergoing a significant internal transformation, particularly in its core business of skin science innovation, which involves changes in operations, products, channels, organization, and branding [10][11]. - The shift from a traffic-driven sales model to a science-based brand communication strategy aims to provide scientifically validated skincare solutions [11]. - Huaxi Biological is focusing on optimizing team structures and improving operational efficiency to enhance overall business quality [11].

Core Viewpoint - The company demonstrated strong brand resilience and internal management capabilities, achieving significant growth in mid-term performance despite challenges faced in the second quarter [1][2]. Financial Performance - In the first half of the year, the company's revenue and net profit attributable to shareholders increased by 22.5% and 20.2% year-on-year, respectively [1]. - The gross margin and net profit margin remained high at approximately 82% and 38% [1]. Revenue Drivers - The main revenue growth drivers were online direct sales through e-commerce platforms (such as JD.com) and offline direct sales, which accounted for 75% of total revenue [1]. - Online direct sales to e-commerce platforms increased by 134%, while offline direct sales grew by 74% year-on-year [1]. Cost Management - The company effectively controlled sales expenses, with the sales expense ratio decreasing by 0.86 percentage points year-on-year, allowing for sufficient marketing investment in the second half of the year [2]. - The good control of sales expenses is attributed to the balanced development across various channels and the reduction in promotional activities due to the product issues in the second quarter [2]. Future Outlook - The company is expected to see a ramp-up in revenue in the second half of the year, driven by the recovery from short-term impacts, increased investment, and the launch of new products [2]. - Long-term focus on scientific research and commercialization in the collagen sector is recommended, with particular attention to upcoming sales during the Double Eleven shopping festival and the progress of medical device certifications [2]. Earnings Forecast - The earnings forecast for 2025-2027 has been slightly adjusted, with expected earnings per share of 2.33, 2.85, and 3.50 RMB, respectively [2]. - A target price of 81.46 HKD has been set for 2025, based on a 32x PE valuation [2].

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The company's revenue for H1 2025 was 1.769 billion yuan, representing a year-on-year growth of 30.8%, while the net profit attributable to the parent company was 186 million yuan, with a year-on-year increase of 5.2%. The second quarter of 2025 saw revenue of 923 million yuan, up 33.5%, but net profit decreased by 23.1% [7][10] - Increased sales expenses impacted overall profit performance, with a sales expense ratio of 56.5% in H1 2025, up 3.4 percentage points year-on-year. The net profit margin was 10.5%, down 2.6 percentage points year-on-year [7][13] - The Marubi brand generated revenue of 1.25 billion yuan, a year-on-year increase of 34.4%, driven by strategic investments in product development and marketing [7] - The PL brand achieved revenue of 516 million yuan, a year-on-year increase of 23.87%, indicating a stable development phase [7] - Online channels accounted for 88.87% of total revenue in H1 2025, with a year-on-year growth of 37.85%, while offline channels saw a decline of 7.07% [7] - The company is expected to continue its multi-brand and multi-channel strategy, focusing on collagen-based skincare products and innovative makeup items [7] Financial Data and Profit Forecast - Total revenue projections for 2025 are estimated at 3.815 billion yuan, with a year-on-year growth rate of 28.5%. The net profit attributable to the parent company is forecasted to be 418 million yuan, reflecting a growth rate of 22.4% [6] - The gross profit margin is expected to be 73.9% in 2025, with a return on equity (ROE) of 11.6% [6] - The company has slightly adjusted its profit forecasts for 2025-2026, now expecting net profits of 420 million yuan and 530 million yuan for 2025 and 2026, respectively [7]

Investment Rating - The investment rating for the company is "Outperform" (maintained) [5] Core Insights - The company achieved a revenue of 859 million yuan in H1 2025, representing a year-on-year increase of 42.43%, and a net profit of 392 million yuan, up 26.65% year-on-year [5] - The growth in revenue is primarily driven by the increase in sales of medical devices and functional skincare products [5] - The company maintains its profit forecast for 2025-2027, expecting net profits of 1,038 million, 1,381 million, and 1,825 million yuan respectively, with corresponding EPS of 9.02, 12.00, and 15.86 yuan per share [5] Revenue Breakdown - Medical device sales generated 708 million yuan in H1 2025, a year-on-year growth of 33.41%, with a gross margin of 95.04% [6] - Functional skincare products achieved revenue of 121 million yuan, marking a significant increase of 152.39% year-on-year, with a gross margin of 70.78% [6] Product Development and Market Expansion - The company has clinically applied over 2.7 million units of recombinant type III humanized collagen, which has received medical device registration approval in Thailand [7] - The company has developed 14 new invention patents, including 4 international patents, and has made significant progress in globalizing its recombinant humanized collagen products [7] Financial Projections - The company forecasts revenue growth from 2,117 million yuan in 2025 to 3,617 million yuan in 2027, with a compound annual growth rate (CAGR) of 29.8% [9] - The projected net profit for 2025 is 1,038 million yuan, increasing to 1,825 million yuan by 2027, reflecting a strong growth trajectory [9]